Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
LLY 
Eli Lilly and Company (LLY)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/17/2025: LLY (2-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
29 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $884.31
1 Year Target Price $884.31
| 16 | Strong Buy |
| 7 | Buy |
| 4 | Hold |
| 1 | Sell |
| 1 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 46.81% | Avg. Invested days 60 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 09/17/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 681.42B USD | Price to earnings Ratio 49.71 | 1Y Target Price 884.31 |
Price to earnings Ratio 49.71 | 1Y Target Price 884.31 | ||
Volume (30-day avg) 29 | Beta 0.47 | 52 Weeks Range 622.41 - 932.73 | Updated Date 09/17/2025 |
52 Weeks Range 622.41 - 932.73 | Updated Date 09/17/2025 | ||
Dividends yield (FY) 0.73% | Basic EPS (TTM) 15.29 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 25.91% | Operating Margin (TTM) 45.81% |
Management Effectiveness
Return on Assets (TTM) 16.55% | Return on Equity (TTM) 86.29% |
Valuation
Trailing PE 49.71 | Forward PE 25.38 | Enterprise Value 721887248174 | Price to Sales(TTM) 12.79 |
Enterprise Value 721887248174 | Price to Sales(TTM) 12.79 | ||
Enterprise Value to Revenue 13.55 | Enterprise Value to EBITDA 36.71 | Shares Outstanding 896456759 | Shares Floating 895437448 |
Shares Outstanding 896456759 | Shares Floating 895437448 | ||
Percent Insiders 0.16 | Percent Institutions 83.86 |
Upturn AI SWOT
Eli Lilly and Company
Company Overview
History and Background
Eli Lilly and Company was founded in 1876 by Colonel Eli Lilly, a pharmaceutical chemist. Initially, it focused on producing quality medicines. Over time, Lilly has become a global leader in pharmaceuticals, researching and developing innovative treatments for various diseases.
Core Business Areas
- Human Pharmaceutical Products: This segment discovers, develops, manufactures, and markets pharmaceutical products for a variety of diseases and conditions including diabetes, oncology, immunology, neuroscience, and other therapies.
- Animal Health: Elanco Animal Health, now a separate publicly traded company (ELAN), was formerly part of Eli Lilly. It focuses on developing and marketing products for livestock and companion animals.
Leadership and Structure
David A. Ricks serves as the Chairman and CEO. The company is structured with various business units focused on specific therapeutic areas and global operations.
Top Products and Market Share
Key Offerings
- Mounjaro (Tirzepatide): A glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist for the treatment of type 2 diabetes. It also shows strong results in weight loss. Competitors include Novo Nordisk (Ozempic, Wegovy) and other GLP-1 receptor agonists. Revenue was $5.16B in 2023. Market share is rapidly growing.
- Revenue (USD billions): 5.16
- Revenue (USD billions): 7.42
- Trulicity (Dulaglutide): A GLP-1 receptor agonist used to treat type 2 diabetes. Competitors include Novo Nordisk (Ozempic) and other GLP-1 receptor agonists. Revenue was $7.42B in 2023. Market share is facing pressure from newer drugs like Mounjaro.
- Revenue (USD billions): 3.86
- Verzenio (Abemaciclib): A CDK4/6 inhibitor used in the treatment of certain types of breast cancer. Competitors include Pfizer (Ibrance) and Novartis (Kisqali). Revenue was $3.86B in 2023. Market share is growing within its specific indication.
- Emgality (Galganezumab): A CGRP monoclonal antibody used for migraine prevention. Competitors include Amgen (Aimovig), Teva (Ajovy), and AbbVie (Qulipta). Revenue was $751.7M in 2023. Market share is fairly competitive.
- Revenue (USD millions): 751.7
Market Dynamics
Industry Overview
The pharmaceutical industry is characterized by intense R&D, regulatory scrutiny, and patent protection. It's driven by innovation and the development of new therapies for unmet medical needs. Aging populations and increased healthcare spending contribute to growth.
Positioning
Eli Lilly is a major player in the pharmaceutical industry, known for its focus on diabetes, oncology, immunology, and neuroscience. Its competitive advantage lies in its strong R&D pipeline and successful commercialization of innovative products.
Total Addressable Market (TAM)
The global pharmaceutical market is estimated to be well over $1 trillion. Lilly is positioned to capture a significant portion of this market through its focused therapeutic areas and innovative pipeline.
Upturn SWOT Analysis
Strengths
- Strong R&D pipeline
- Successful product launches (e.g., Mounjaro)
- Diversified portfolio across key therapeutic areas
- Strong financial performance
- Experienced leadership team
Weaknesses
- Reliance on key products with patent expirations
- High R&D costs
- Regulatory risks
- Dependence on successful clinical trials
- Competition in key therapeutic areas
Opportunities
- Expansion into new therapeutic areas
- Strategic acquisitions and partnerships
- Growth in emerging markets
- Development of innovative drug delivery systems
- Leveraging digital health technologies
Threats
- Patent expirations of key products
- Generic competition
- Pricing pressures from governments and payers
- Unsuccessful clinical trials
- Adverse regulatory decisions
Competitors and Market Share
Key Competitors
- NVO
- MRK
- PFE
- ABBV
Competitive Landscape
Eli Lilly faces intense competition from other major pharmaceutical companies. Its competitive advantage lies in its innovative products and strong R&D pipeline, but it must continue to innovate to maintain its position.
Major Acquisitions
Sigilon Therapeutics
- Year: 2023
- Acquisition Price (USD millions): 309
- Strategic Rationale: Expanded Lilly's research in Type 1 Diabetes. The company is focussed on developing encapsulated cell therapies.
DICE Therapeutics
- Year: 2023
- Acquisition Price (USD millions): 1400
- Strategic Rationale: Expanding Lilly's presence in immunology by acquiring an oral IL-17 inhibitor program.
Growth Trajectory and Initiatives
Historical Growth: Lilly has experienced significant growth in recent years, driven by the success of its key products, particularly in the diabetes and oncology areas.
Future Projections: Analysts project continued growth for Lilly, driven by its strong R&D pipeline and the expected launch of new products. Revenue is expected to increase significantly over the next few years.
Recent Initiatives: Lilly is actively investing in R&D, expanding its presence in emerging markets, and pursuing strategic acquisitions and partnerships.
Summary
Eli Lilly is a strong pharmaceutical company with a robust pipeline and successful product launches, particularly Mounjaro. Its focus on diabetes, oncology, and immunology positions it well for future growth. However, patent expirations and pricing pressures remain key challenges. Continuing investment in R&D is critical for maintaining its competitive edge.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Eli Lilly and Company Investor Relations
- SEC Filings
- Market Research Reports
- Analyst Estimates
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market conditions and company performance are subject to change. Conduct your own research before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Eli Lilly and Company
Exchange NYSE | Headquaters Indianapolis, IN, United States | ||
IPO Launch date 1978-01-13 | Chairman, CEO & President Mr. David A. Ricks | ||
Sector Healthcare | Industry Drug Manufacturers - General | Full time employees 47000 | Website https://www.lilly.com |
Full time employees 47000 | Website https://www.lilly.com | ||
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; Verge Genomics; collaboration with AdvanCell to advance novel targeted alpha therapies for the treatment of cancer; and Chugai Pharmaceutical Co., Ltd, as well as Strategic Collaboration with Eli Lilly to advance development of its myeloid engager platform for autoimmune disease. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.